Protalix BioTherapeutics Receives Outperform Rating from Oppenheimer (PLX)

Protalix BioTherapeutics (NYSE: PLX)‘s stock had its “outperform” rating restated by analysts at Oppenheimer in a research report issued to clients and investors on Tuesday. They currently have a $7.00 price target on the stock.

Protalix BioTherapeutics (NYSE: PLX) traded up 1.24% on Tuesday, hitting $5.72. Protalix BioTherapeutics has a 1-year low of $4.71 and a 1-year high of $7.70. The stock’s 50-day moving average is currently $5.67. The company’s market cap is $526.2 million.

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.